Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
XmAb819-01
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT05433142 ↗
- Recruiting
- Xencor, Inc.
- Standard
We haven't built an HCP commentary report on XmAb819-01 (XmAb819 in Clear Cell Renal Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on XmAb819-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- XmAb819
- Arms
- Dose Escalation and Expansion · Experimental
- Enrollment
- 307 (estimated)
- Primary outcomes
- Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)
- Incidence of dose limiting toxicities (DLTs)
- Sponsor
- Xencor, Inc.
- Start
- Jun 13, 2022
- Primary completion
- Feb 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05433142 · updated Aug 3, 2026